Pulmonary disease caused by a newly identified mycobacterium: Mycolicibacterium toneyamachuris: a case report

BMC Infect Dis. 2020 Nov 25;20(1):888. doi: 10.1186/s12879-020-05626-y.

Abstract

Background: Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is becoming a significant health burden. Recent advances in analysis techniques have allowed the accurate identification of previously unknown NTM species. Here, we report a case of NTM-PD caused by a newly identified mycobacteria in an immunocompetent patient.

Case presentation: A 44-year-old woman was referred to our hospital due to the frequent aggravation of her chronic respiratory symptoms, with NTM-PD-compatible computed tomography findings. Unidentified mycobacterium was repeatedly isolated from respiratory specimens and we diagnosed her as NTM-PD of unidentified mycobacterium. Subsequent whole-genome analysis revealed that the unidentified mycobacterium was a novel mycobacterium genetically close to Mycolicibacterium mucogenicum. We started combination therapy with clarithromycin, moxifloxacin, amikacin, and imipenem/cilastatin, referring to drug sensitivity test results and observed its effect on M. mucogenicum infection. Her symptoms and radiological findings improved significantly.

Conclusion: We report a case of NTM-PD caused by a newly identified mycobacteria, Mycolicibacterium toneyamachuris, genetically close to M. mucogenicum. This pathogenic mycobacterium showed different characteristics from M. mucogenicum about clinical presentation and drug sensitivity. The clinical application of genomic sequencing will advance the identification and classification of pathogenic NTM species, and enhance our understanding of mycobacterial diseases.

Keywords: Mycolicibacterium mucogenicum; Mycolicibacterium toneyamachuris; Non-tuberculous mycobacteria; Rapid growing mycobacteria.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Diagnostic Tests, Routine
  • Female
  • Humans
  • Lung Diseases / diagnosis*
  • Lung Diseases / microbiology
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing / methods
  • Mycobacterium Infections, Nontuberculous / diagnosis*
  • Mycobacterium Infections, Nontuberculous / drug therapy
  • Mycobacterium Infections, Nontuberculous / microbiology
  • Nontuberculous Mycobacteria / drug effects
  • Nontuberculous Mycobacteria / genetics*
  • Nontuberculous Mycobacteria / isolation & purification*
  • Treatment Outcome
  • Whole Genome Sequencing / methods

Substances

  • Anti-Bacterial Agents